Sionna Therapeutics (SION) Interest Expenses (2024 - 2025)
Sionna Therapeutics (SION) reported Interest Expenses of $168.0 million for Q4 2025, up 225.56% on a YoY basis from $51.6 million in Q4 2024, and up 225.56% sequentially from $51.6 million in Q4 2024.
Sionna Therapeutics (SION) Interest Expenses (2024 - 2025) Analysis & Trends
Sionna Therapeutics (SION) has 2 years of Interest Expenses data on file, last reported at $168.0 million in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 225.56% year-over-year to $168.0 million; the trailing twelve-month figure through Dec 2025 stood at $168.0 million (up 225.56% YoY), and the FY2025 full-year result was $168.0 million, up 225.56% from the prior year.
- Interest Expenses improved to $168.0 million in Q4 2025, from $51.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $168.0 million in Q4 2025 to a low of $51.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Sionna Therapeutics | 2.04 Bn | 2.04 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 168.01 Mn |
| Dec 31, 2025 | 168.01 Mn |
| Dec 31, 2024 | 51.61 Mn |
| Dec 31, 2024 | 51.61 Mn |